Swanink, C M, Vercoulen, J H, Galama, J M et al. · The Journal of infectious diseases · 1996 · DOI
This study compared immune system markers in blood samples from 76 ME/CFS patients and 69 healthy controls to see if immune abnormalities could explain fatigue severity. Researchers found one immune marker (CD11b on CD8 cells) was lower in ME/CFS patients, but most other immune measures were similar between groups, and none of these markers correlated with how severe a patient's fatigue or depression was.
This study addressed a critical question in ME/CFS research: whether measurable immune abnormalities drive symptom severity. By directly testing whether immune markers could serve as diagnostic or prognostic tools, the research provides important negative evidence that helps redirect diagnostic efforts and clarifies which immunologic features are associated with the disease versus which are clinically meaningful.
This study does not establish that immune dysfunction plays no role in ME/CFS pathogenesis—only that the specific markers measured do not correlate with symptom severity or functional impairment in individual patients. Absence of correlation with fatigue scores does not mean the immune changes are irrelevant; they may still contribute to disease mechanisms in ways not captured by these particular clinical measures. Cross-sectional design prevents determination of causality.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.